Sign in
Taking people in United StatesPhase 1

Radiotherapy with TTI-101 for Pancreatic Cancer That Is Borderline Resectable or Locally Advanced

Tests radiation with TTI-101 in adults with pancreatic cancer that is locally advanced.

Key facts

Who runs it
Washington University School of Medicine
Where
Aurora and St Louis, United StatesSee the 2 sites
Trial code
Registry title
Radiotherapy in Combination With TTI-101 in Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma
Status
Recruiting
Phase
Phase 1
People taking part
24 people, planned
Started
16 Jan 2024
Expected to end
30 Jun 2029
Type of study
Interventional, 4 groups
Treatments tested
  • TTI-101
  • Stereotactic body radiation therapy
Record updated
6 November 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with borderline resectable or locally advanced pancreatic cancer (pancreatic adenocarcinoma). It tests radiotherapy (SBRT) together with the drug TTI-101.

Age
18 years or older
Sex
All sexes can join
Disease stage
Pancreatic adenocarcinoma confirmed by pathology, borderline resectable or locally advanced by NCCN guidelines, with no expected arterial resection or reconstruction
Earlier treatment
Borderline resectable disease: standard induction chemotherapy finished 1 to 3 weeks before TTI-101 + SBRT starts. Locally advanced disease: no timing limit. No radiation to the pancreatic cancer in the past 2 years.

Main reasons for not taking part

  • Radiation to the pancreatic cancer in the past 2 years
  • Another cancer that could affect the safety or results of the study
  • Uncontrolled illness, such as an active infection or chronic pancreatitis
  • Serious heart problems, such as heart failure NYHA Class III or IV or a heart attack in the last 12 months
  • Pregnant or breastfeeding

The registry criteria, word for word

Show all 27 criteriaShow less

Who can take part

  • Pathologically confirmed pancreatic adenocarcinoma that is borderline resectable or locally advanced as defined by NCCN guidelines, with no expected arterial resection/reconstruction
  • Patients who are borderline resectable must have completed standard of care induction chemotherapy between 1 and 3 weeks prior to planned start of TTI-101 + SBRT. Patients who exceed this window may be considered for enrollment if they complete an additional cycle of induction chemotherapy prior to initiation of study treatment (per provider discretion). The receipt and/or amount of induction chemotherapy cycles allowed will be left to the discretion of the treating medical oncologist. There is no timing restriction or chemotherapy receipt for patients with locally advanced disease
  • At least 18 years of age
  • ECOG performance status ≤ 2
  • Adequate bone marrow and organ function as defined below:; Absolute neutrophil count ≥ 1.0 K/cumm; Platelets ≥ 70 K/cumm; Hemoglobin ≥ 9.0 g/dL (patients may be transfused to meet this criterion); Total bilirubin ≤ 2 mg/dL; AST(SGOT)/ALT(SGPT) ≤ 3.0 x IULN; Serum albumin ≥ 2.8 g/dL; Ionized calcium ≤ 1.5 mmol/L, calcium ≤ 12 mg/dL, or corrected serum calcium ≤ IULN); Measured creatinine clearance > 40 mL/min or calculated creatinine clearance > 40 mL/min by Cockcroft-Gault or by 24-hour urine collection for determination of creatinine clearance (calculations in protocol)
  • Able to swallow pills and has been deemed an appropriate candidate for investigational TTI-101 treatment based on the opinion of both the treating radiation oncologist and the treating medical oncologist
  • INR and aPTT ≤ 1.5 x IULN unless patient is receiving anticoagulant therapy (in which case INR and PTT must be within therapeutic range of intended use of anticoagulants)
  • The effects of TTI-101 on the developing human fetus are unknown. For this reason, women of childbearing potential and men must agree to use at least 1 highly effective method of contraception from screening through the duration of study participation, and for 30 days after last dose of TTI-101. Should a woman become pregnant or suspect she is pregnant while participating in this study or should a man suspect he has fathered a child, s/he must inform the treating physician immediately
  • Agreement to adhere to Lifestyle Considerations throughout study duration
  • Ability to understand and willingness to sign an IRB approved written informed consent document

Who cannot take part

  • Prior irradiation of pancreatic cancer in the past 2 years
  • Prior or concurrent malignancy whose natural history has the potential to interfere with the safety or efficacy assessment of the investigational regimen. Patients with prior or concurrent malignancy that does NOT meet that definition are eligible for this trial
  • Currently receiving any other investigational agents or has participated in a study of an investigational agent or using an investigational device overlapping with study treatments within 3 months preceding study entry at the discretion of the PI
  • Uncontrolled intercurrent illness including but not limited to: ongoing or active infection (fungal, bacterial, or viral (including COVID-19)), sepsis, acute and chronic active infectious disorders (including viral and nonmalignant medical illnesses that are uncontrolled or whose control may be jeopardized by the complications of this study therapy), and chronic pancreatitis. Patients with a recent COVID-19 diagnosis must have fully recovered from all COVID-19 symptoms for 2 weeks prior to the start of study treatment
  • Ongoing toxicity due to induction chemotherapy, unless returned to baseline or grade 1 or less (except alopecia and labs noted in inclusion criterion #5)
  • Has had major surgery within 3 weeks prior to starting TTI-101 or has not recovered from major side effects due to surgery
  • History of cerebrovascular accident or stroke within the previous 2 years
  • HIV-infected if not on effective anti-retroviral therapy with undetectable viral load for 6 months. Patients with HIV who are receiving effective anti-retroviral therapy and have had an undetectable viral load for at least 6 months are eligible. HIV testing not required in the absence of known history of infection
  • History of hepatitis C virus (HCV) infection that has not been cured or that has a detectable viral load. Patients with a history of HCV that has been treated and cured are eligible. Patients with HCV infection who are currently on treatment and have an undetectable HCV viral load are eligible. HCV testing not required in the absence of known history of infection
  • A history of allergic reactions attributed to compounds of similar chemical or biologic composition to TTI-101 or other agents used in the study
  • History of hepatic encephalopathy
  • Evidence of bleeding diathesis or significant coagulopathy (in the absence of therapeutic anticoagulation)
  • History of malabsorption or other chronic gastrointestinal disease or condition that may hamper compliance or absorption of TTI-101
  • Evidence of chronic hepatitis B virus (HBV) that is detectable on suppressive therapy. Patients with evidence of chronic HBV infection with undetectable HBV viral load on suppressive therapy are eligible. HBV testing not required in the absence of known history of infection
  • Significantly impaired cardiac function such as symptomatic congestive heart failure with NYHA Class III or IV, unstable angina pectoris, myocardial infarction within the last 12 months prior to study entry, serious cardiac arrhythmia (including QTc prolongation of > 470 ms and/or pacemaker), or prior diagnosis of congenital long QT syndrome
  • Pregnant and/or breastfeeding. Women of childbearing potential must have a negative serum or urine pregnancy test within 5 days of study entry
  • Presence of pleural effusion, pericardial effusion, or ascites requiring recurrent drainage procedures (once monthly or more frequent). Participants with indwelling catheters for control of effusions or ascites are allowed

Where in United States

  • University of ColoradoAurora, United StatesContact: Sana Karam, M.D., Ph.D.No longer taking part
  • Washington University School of MedicineSt Louis, United StatesContact: Sana Karam, M.D., Ph.D.Taking people

About the trial

What the trial wants to find out

The survival rate for patients with pancreatic cancer remains at a dismal 10% or less at 5 years, and although trials integrating stereotactic body radiation therapy (SBRT) alone have shown improvement in local control, initial invigoration of immune response, and relief of symptom burden, SBRT has not demonstrated any improvement in survival. Preclinical research has established that STAT3 inhibition given concurrently with SBRT and in the maintenance phase acts as a synergistic agent that enhances the pro-inflammatory effects of SBRT while reducing its undesired effects (including fibrosis and immunosuppression). This study exploits the window of opportunity post-chemotherapy to advance the hypothesis that the addition of STAT3 inhibition in combination with SBRT will be safe and will enhance 2-year progression-free survival.

The 4 groups in the trial

  • TTI-101 + SBRT Dose Level 0 (original starting dose)Treatment being tested

    * Treatment consists of TTI-101 by mouth twice daily at 400 mg and SBRT (5 fractions of 6.6 Gy each) over the course of 3 weeks. * After combination therapy is concluded, patients who entered the study as locally advanced will receive up to 10 additional weeks of TTI-101 monotherapy (until a tumor biopsy that will occur between Weeks 9 and 13). After discontinuation of TTI-101, patients will receive SOC chemotherapy as part of their routine care (not dictated by study participation). * Patients who entered the study as borderline resectable will be assessed following the initial 3 weeks of treatment. If they have reverted to resectable, they will undergo surgery, followed by optional adjuvant chemotherapy at the discretion of their treating team. If they are unresectable, they will follow the path of the locally advanced patients (up to 10 weeks of TTI-101 monotherapy, followed by disease assessment, followed by SOC chemotherapy).

    Treatment: TTI-101 and Stereotactic body radiation therapy

  • TTI-101 + SBRT Dose Level -1 (WUSM starting dose)Treatment being tested

    * Treatment of TTI-101 by mouth twice daily at 200 mg \& SBRT (3 fractions of 6 Gy each, approximately every other day but may be given over 2-3 weeks) over the course of 3 weeks. * After combination therapy, patients who entered the study as locally advanced will receive up to 10 additional weeks of TTI-101 monotherapy (until a tumor biopsy that will occur between Weeks 9-13 if possible). After discontinuation of TTI-101, patients will receive SOC chemotherapy as part of their routine care (not dictated by study participation). * Patients who entered the study as borderline resectable will be assessed following the initial 3 weeks of treatment. If they have reverted to resectable, they will undergo surgery, followed by optional adjuvant chemotherapy at the discretion of their treating team. If they are unresectable, they will follow the path of the locally advanced patients (up to 10 weeks of TTI-101 monotherapy, followed by disease assessment, followed by SOC chemotherapy).

    Treatment: TTI-101 and Stereotactic body radiation therapy

  • TTI-101 + SBRT Dose Level -2Treatment being tested

    * Treatment consists of TTI-101 by mouth twice daily at 200 mg and SBRT (1 fraction of 12 Gy each) over the course of 3 weeks. * After combination therapy is concluded, patients who entered the study as locally advanced will receive up to 10 additional weeks of TTI-101 monotherapy (until a tumor biopsy that will occur between Weeks 9 and 13 if possible). After discontinuation of TTI-101, patients will receive SOC chemotherapy as part of their routine care (not dictated by study participation). * Patients who entered the study as borderline resectable will be assessed following the initial 3 weeks of treatment. If they have reverted to resectable, they will undergo surgery, followed by optional adjuvant chemotherapy at the discretion of their treating team. If they are unresectable, they will follow the path of the locally advanced patients (up to 10 weeks of TTI-101 monotherapy, followed by disease assessment, followed by SOC chemotherapy).

    Treatment: TTI-101 and Stereotactic body radiation therapy

  • TTI-101 + SBRT Expansion PhaseTreatment being tested

    * Treatment consists of TTI-101 by mouth twice daily at the RP2D dose and SBRT (at the RP2D dose and timing) over the course of 3 weeks. * After combination therapy is concluded, patients who entered the study as locally advanced will receive up to 10 additional weeks of TTI-101 monotherapy (until a tumor biopsy that will occur between Weeks 9 and 13 if possible). After discontinuation of TTI-101, patients will receive SOC chemotherapy as part of their routine care (not dictated by study participation). * Patients who entered the study as borderline resectable will be assessed following the initial 3 weeks of treatment. If they have reverted to resectable, they will undergo surgery, followed by optional adjuvant chemotherapy at the discretion of their treating team. If they are unresectable, they will follow the path of the locally advanced patients (up to 10 weeks of TTI-101 monotherapy, followed by disease assessment, followed by SOC chemotherapy).

    Treatment: TTI-101 and Stereotactic body radiation therapy

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Phase I/IB Trial of Radiotherapy in Combination With TTI-101 in Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma
Plain-language title
Radiotherapy with TTI-101 for Pancreatic Cancer That Is Borderline Resectable or Locally AdvancedGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
6 November 2026